CD8A and neoplasm: Upon tracking the case (Table S4), Patient 3 (O1), who exhibited low levels of PDCD1 in CD8+ T cells, showed no improvement after using a PD‐1 inhibitor, camrelizumab, combined with paclitaxel‐albumin and tegafur for two periods, although the patient had a programmed cell death ligand 1 (PD‐L1) combined positive score (CPS, ratio of the number of all PD‐L1‐expressing cells to the number of all tumour cells) ≥ 1.